eTSF
BehavioraleTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
NCT Number: NCT06722690
The goal of this clinical trial is to learn if the eTSF intervention is feasible among Latinx young adults with alcohol use disorder. The main questions it aims to answer are:
* Is eTSF feasible? * Is eTSF effective in reducing alcohol use and increasing 12-step engagement compared to the control condition? The control condition will receive educational materials on drinking problems and a list of local/online AA meetings Participants will * Be randomly assigned to either the eTSF condition or the control condition. * Fill out the baseline online survey. * Go through the eTSF app/control materials. * And at 3 months post-baseline, fill out the follow-up online survey.
Trial opening soon.
Get Notified18 year–29 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
Educational materials on drinking problems and a list of local/online AA meetings.
Time frame: Every 4 weeks up to 2 years
Recruitment feasibility will be measured by the number of participants screened and enrolled each month.
Time frame: From recruitment to baseline assessment up to two years
Randomization feasibility will be measured by the number of baseline demographic variables with statistically significant group differences.
Time frame: From recruitment to the end of the trial at three months.
Retention/attrition feasibility will be measured by retention rates in each condition.
Time frame: From recruitment to the end of the trial at three months.
Adherence feasibility will be measured by the percentage of eTSF app components used by the eTSF condition participants.
Time frame: From recruitment to the end of the trial at three months.
Assessment feasibility will be measured by the proportion of missing data in each assessment.
Time frame: From baseline to the end of treatment at three months.
Intervention credibility will be measured using a single-item question: "On a scale from 1 to 5, where 1 indicates 'not at all' and 5 indicates 'very much,' to what extent do you believe this treatment will be beneficial for you?" Only eTSF condition participants will receive this measure.
Time frame: From baseline to the end of treatment at three months.
Intervention satisfaction will be measured using the mHealth Satisfaction Questionnaire, which has a total score range from 14 to 42. Higher total scores indicate greater user satisfaction with the mHealth app.
Time frame: From baseline to the end of treatment at three months.
Acceptability will be measured using the Abbreviated Acceptability Rating Profile, which scores range from 8 to 48. Higher scores indicate greater acceptability of the intervention.
Time frame: From baseline to the end of treatment at three months.
Intervention engagement will be automatically recorded by the app during the study period and be measured in terms of app opening frequency, time spent on the app per use session (i.e., the time between opening and closing the app), most frequently used intervention component, time spent per intervention component, the completion rate of each selected component, reports of technical problems.
Time frame: From baseline to the end of treatment at three months.
Alcohol use will be measured using the Time-Line Follow-Back (TLFB) method-Form 90, which helps participants recall and mark days on which they used alcohol during the past 90 days.
Time frame: From baseline to the end of treatment at three months.
12-Step fellowship engagement will be measured with the Multi-Dimensional Mutual-help Activity Scale (MDMAS), which measures seven dimensions of experience (meeting attendance, meeting participation, fellowship involvement, step work, mandated attendance, affiliation, and safety). Total score ranges from 32-160 with higher scores within indicating greater engagement.
Time frame: From baseline to the end of treatment at three months.
Drinking consequences will be measured with the Short Inventory of Problems (SIP-2R). Score ranges from 0-45 with higher scores indicating a greater frequency of experiencing problems related to substance use.
Time frame: From baseline to the end of treatment at three months.
Drug use will be measured with the aforementioned TLFB-Form 90
Time frame: From baseline to the end of treatment at three months.
Psychological distress will be assessed with the 18-item Brief Symptom Inventory. Score ranges 0-72 and higher scores indicate greater levels of psychological distress.
Contact information is provided by the study sponsor or research team.
Tulane University
Other
Culturally Adapting Spiritually and Technologically Informed Interventions to Reduce Alcohol-Related Health Disparities Among Latinx Young Adults- Aim 3 RCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07706660
Affective Symptoms, Alcohol Use Disorder (AUD)
Warsaw, Mazovian, Poland
View Trial DetailsNCT07148843
Alcohol Abstinence, Alcohol Use Disorder (AUD)
Baltimore, Maryland, United States
View Trial DetailsNCT07690423
Alcohol Use Disorder (AUD), Alcohol-Related Disorders
View Trial DetailsNCT07279363
Alcohol Use Disorder (AUD), Alcohol-Related Disorders
Rochester, New York, United States
View Trial Details